KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial.

Heinz-Josef Lenz, Tianshu Liu, Emerson Y Chen, Zsolt Horváth, Igor Bondarenko, Iwona Danielewicz, Michele Ghidini, Pilar García-Alfonso, Robert Jones, Matti Aapro, Yanqiao Zhang, Jufeng Wang, Wayne Wang, Jennifer Adeleye, Andrew Beelen, Joleen Hubbard

JNCI Cancer Spectr 9(1) pkae116

PMID39579142
PMCIDPMC11708780
DOI10.1093/jncics/pkae116
发表日期2024-11-23
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

BACKGROUND: In metastatic colorectal cancer (mCRC), improvements in survival from combining leucovorin/fluorouracil/oxaliplatin/irinotecan (FOLFOXIRI) with bevacizumab have come at the risk of increased rates of high-grade toxicities. Trilaciclib is indicated to decrease the incidence of chemotherapy-induced myelosuppression in patients receiving standard-of-care chemotherapy for extensive-stage small cell lung cancer. METHODS: Patients with untreated mCRC were randomly assigned 1:1 to trilaciclib (n = 164) or placebo (n = 162) prior to FOLFOXIRI/bevacizumab for up to 12 cycles (induction), followed by trilaciclib or placebo prior to fluorouracil/leucovorin/bevacizumab (maintenance). Co-primary endpoints were duration of severe (grade 4) neutropenia (DSN) in cycles 1-4 and occurrence of severe neutropenia (SN) during induction. Secondary endpoints included antitumor efficacy, survival, and safety. RESULTS: The study met its co-primary endpoints. Administering trilaciclib prior to FOLFOXIRI/bevacizumab resulted in significant reductions in DSN in cycles 1-4 vs placebo (mean, 0.1 vs 1.3 days; P < .001) and occurrence of SN during induction (1.3% vs 19.7%; adjusted relative risk [96% CI] = 0.07 [0.0 to 0.3]; P < .001). Grade 3/4 adverse events, including neutropenia, diarrhea, and leukopenia, were less frequent with trilaciclib vs placebo (64.8% vs 73.1%). Trilaciclib was associated with fewer chemotherapy dose reductions and delays and with reduced administration of supportive therapies, compared with placebo. Objective response rate (41.6% vs 57.1%; P = .009) and median progression-free survival (10.3 vs 13.1 months; P < .001) were significantly lower with trilaciclib vs placebo. CONCLUSIONS: Administering trilaciclib prior to FOLFOXIRI/bevacizumab protected the neutrophil lineage from the effects of chemotherapy-induced myelosuppression. However, antitumor efficacy endpoints favored placebo. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04607668.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 3

Figure 3. Kaplan-Meier curve for PFS of the mITT population.

PFS_of_mITT_population

PFS

Figure 3 · Panel PFS_of_mITT_population

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel PFS_of_mITT_population 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:extreme jump曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Trial profile.
非 KM Figure
Figure 2Figure 2. Summary of myeloprotection endpoints.
非 KM Figure